联用替格瑞洛和阿司匹林治疗心肌梗死的临床疗效研究  

Clinical efficacy of combination of ticagrelor and aspirin in the treatment of myocardial infarction

作　　者：马小俊 廖嘉宝 陶青 MA Xiao-jun;LIAO Jia-bao;TAO Qing(Department of Emergency,Shunde Hospital of Southern Medical University(the First People's Hospital of Shunde),Foshan 528300,China)

机构地区：[1]南方医科大学顺德医院急诊科(佛山市顺德区第一人民医院),528300

出　　处：《中国实用医药》2024年第23期92-95,共4页China Practical Medicine

摘　　要：目的探究联用替格瑞洛和阿司匹林治疗心肌梗死的临床疗效。方法86例心肌梗死患者为研究对象,以治疗方法的不同分为两组,其中43例给予联用替格瑞洛和阿司匹林治疗的患者为研究组,另外43例给予阿司匹林治疗的患者为对照组。比较两组患者炎症因子、心功能指标、心肌酶指标及氨基末端脑钠肽前体(NT-proBNP)、不良事件发生率。结果治疗后,研究组患者C反应蛋白(CRP)为(27.30±2.95)mg/L、肿瘤坏死因子α(TNF-α)为(2.15±0.30)ng/L、白细胞介素6(IL-6)为(170.00±10.81)ng/L,均低于对照组的(33.08±3.14)mg/L、(3.00±0.71)ng/L、(180.72±11.54)ng/L,差异明显(P<0.05)。治疗后,研究组患者左室射血分数(LVEF)(46.41±2.14)%高于对照组的(42.90±2.00)%,左室收缩末期内径(LVESD)(34.47±0.42)mm、左室舒张末期内径(LVEDD)(58.22±2.58)mm低于对照组的(36.99±0.99)、(60.02±3.01)mm,差异明显(P<0.05)。治疗后,研究组患者NT-proBNP(119.77±50.47)pg/ml、肌酸激酶同工酶(CK-MB)(30.45±1.99)U/L、肌钙蛋白I(cTnI)(0.58±0.03)μg/L低于对照组的(388.87±100.24)pg/ml、(37.47±2.57)U/L、(0.92±0.06)μg/L,差异明显(P<0.05)。研究组患者不良事件发生率6.98%低于对照组的23.26%,差异明显(P<0.05)。结论替格瑞洛与阿司匹林联合应用治疗心肌梗死具有显著的临床疗效,能改善患者的心功能指标,增强血管内皮功能,降低不良事件的发生率,并且在血小板聚集功能方面表现优越,值得临床上大力推广和使用该联合方案。Objective To explore the clinical efficacy of combination of ticagrelor and aspirin in the treatment of myocardial infarction.Methods 86 patients with myocardial infarction were studied,and were divided into two groups by different treatment methods,among which 43 patients treated with combination of ticagrelor and aspirin were selected as the study group,and the other 43 patients treated with aspirin as the control group.The inflammatory factors,cardiac function indicators,myocardial enzyme indicators,N-terminal pro-brain natriuretic peptide(NT-proBNP)and incidence of adverse events were compared between the two groups.Results After treatment,the C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin6(IL-6)were(27.30±2.95)mg/L,(2.15±0.30)ng/L and(170.00±10.81)ng/L in the study group,which were lower than(33.08±3.14)mg/L,(3.00±0.71)ng/L and(180.72±11.54)ng/L in the control group,and the difference was significant(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)of(46.41±2.14)%in the study group was higher than(42.90±2.00)%in the control group;the left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD)in the study group were(34.47±0.42)and(58.22±2.58)mm,which were lower than(36.99±0.99)and(60.02±3.01)mm in the control group;the difference was significant(P<0.05).After treatment,NT-proBNP of the study group was(119.77±50.47)pg/ml,the creatine kinase isoenzyme(CK-MB)was(30.45±1.99)U/L,and the troponin I(cTnI)was(0.58±0.03)μg/L,which were lower than(388.87±100.24)pg/ml,(37.47±2.57)U/L,and(0.92±0.06)μg/L of the control group,and the difference was significant(P<0.05).The incidence of adverse events of 6.98%in the study group was significantly lower than 23.26%in the control group(P<0.05).Conclusion The combination of ticagrelor and aspirin has significant clinical efficacy in the treatment of myocardial infarction,which can improve the cardiac function indicators of patients,enhance their vascular endothelial function,reduc

关 键 词：心肌梗死 替格瑞洛 阿司匹林 临床疗效 不良事件 

分 类 号：R542.22[医药卫生—心血管疾病]